The sensitivities and specificities of the IgA and IgG antigliadin antibody and the IgA antireticulin antibody have been compared with the recently described endomysial antibody directed against the basement membrane of smooth muscle in monkey oesophagus. One hundred and seventeen patients with adult coeliac disease (21 untreated), 84 patients with inflammatory bowel disease, systemic lupus erythematosus and rheumatoid arthritis (comprising the disease control group), 47 normal controls and a miscellaneous group of 29 patients, who were selected because of a positive reticulin staining pattern, were investigated. These results were correlated with the degree of abnormality of the intestinal mucosa in patients with adult coeliac disease. Endomysial antibodies were found in all patients with untreated coeliac disease and subtotal villous atrophy and in 47% of patients on a non-strict gluten free diet. One patient on a strict gluten free diet was positive and had partial villous atrophy while all patients in disease control groups were negative. Results were variable with the antireticulin and antigliadin antibodies. Sensitivity and correlation with subtotal villous atrophy in the untreated patients was 100%. It is concluded that the endomysial antibody is superior to other current antibody tests and should be used in preference for the diagnosis of coeliac disease.
The 'gold standard' for the diagnosis of coeliac disease remains the jejunal biopsy. Over the last 30 years, however, most workers have been searching for a less invasive test for both screening and diagnostic purposes. Tests looking for circulating antibodies to gluten, gliadin or reticulin, using immunofluorescence or the enzyme linked immunosorbent assay (ELISA) techniques' '3 have been considered potential screening tests for coeliac disease. The sensitivities and specificities of these tests have varied from centre to centre but have been improved by using class specific immunoglobulin.' '" This variability has been a drawback to their diagnostic use.
Chorzelski et al'7 described a new antibody directed against the membrane of smooth muscle bundles of primates. This endomysial antibody was present in patients with dermatitis herpetiformis and coeliac disease. This antibody may be closely related to the reticulin antibody. The antibody titres have been shown to correlate with the severity of the histopathological abnormalities in the jejunal mucosa' although the numbers of patients investigated are small.
The aim of our study was to compare the sensitivities and specificities of the antigliadin antibody, antireticulin antibody and endomysial antibody using ELISA and immunofluorescent techniques in a variety of patient groups.
Methods

PATIENTS
One hundred and seventeen patients with adult coeliac disease (21 untreated Sections of Marmoset monkey oesophagus were used for the endomysial antibody estimations and compared with the commercially available oesophageal sections (BioDiagnostics, Upton upon Severn). Positive and negative controls were used for each batch and reproducibility of the tests was checked on the same day and on different days.
ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)
Antibodies to gliadin were estimated using the enzyme-linked immunosorbent assay'8 following modification (Lloyd Davies et al unpublished data). A strongly positive serum was used to produce a standard curve, this serum had been given an arbitrary value of 100 units at a specific dilution (IgG 1:500, IgA 1:100). The IgA and IgG antigliadin antibody distribution within a normal population had been established by comparing absorbances of a large number of samples generated from a blood bank population to the standard curve of the strongly positive serum and a reporting regime established. Studies were carried out on reproducibility during modification of the ELISA, the method was found to be highly reproducible. PVA=partial villous atrophy; SVA= GFD= gluten free diet.
-sub total sillous atrophy; The aim of our study was to compare and contrast the sensitivities and specificities of the endomysial antibody compared with antireticulin and antigliadin antibodies. We measured these antibodies using the immunofluorescent test for the endomysial and antireticulin antibodies and the ELISA test for the antigliadin antibodies. The immunofluorescent test for the antigliadin antibody was not used as it has been shown to be unreliable. Our results show that the antibody was 100% sensitive for patients with untreated coeliac disease. The antireticulin antibody although not so sensitive, showed a very high degree of specificity. Both the endomysial and IgA antireticulin antibodies showed a positive predictive value for detecting the disease in approximately 91% of patients; the latter figure for the endomysial antibody is not 100% as two patients (with insulin independent diabetes mellitus and Hashimoto's thyroiditis disease) were shown to be positive.7These patients had no recorded symptoms of malabsorption and have refused further investigation. It is known, however, that there is an increased frequency of coeliac disease in patients with insulin dependent diabetes mellitus2526 and autoimmune diseases are also seen with increased frequency in patients with coeliac disease27; it is therefore possible that these patients may have coeliac disease.
Our results are not in accordance with those of McMillan et all' who found that 89% of their patients with untreated coeliac disease had a positive endomysial antibody (measured by immunofluorescence) compared with 100% positivity obtained with gliadin IgA using an ELISA test. The titres of patients' sera used in both tests were not given in their report. We used a titre of 1:2-5 for the endomysial antibody immunofluorescence as no residual staining was seen at this titre and with the ELISA there was a definite cut off point between positive and negative. Our IgA antigliadin antibody only showed a 91% positivity in patients with untreated coeliac disease while the endomysial antibody was 100% positive.
Rossi et a129 assessed the relationship of the endomysial antibody to the severity of the mucosal lesions. They found that all patients with detectable endomysial antibody at the time of biopsy exhibited the more advanced changes of villous atrophy. Endomysial antibody was not detected in 160 subjects with diarrhoea, 18 of whom had mild villous atrophy. Their conclusion was that endomysial antibody appeared to be specifically correlated to the intestinal histopathology of coeliac disease and did not appear to be a non-specific marker for mucosal atrophy. One of their patients, however, who was initially positive for endomysial antibody, had an intestinal infestation with Giardia lamblia, an intestinal biopsy performed after treatment for the parasite showed normal histology and the patient negative endomysial antibody. Volta et al/" in their recent report noted that some of their patients were endomysial antibody positive although their jejunum had recovered; endomysial antibody was seen at a higher frequency in children rather than adults and in their study the prevalence of IgA endomysial and antigliadin antibodies were not statistically different. In our non-strict group although six of nine patients with partial villous atrophy were endomysial antibody positive we were surprised to find three patients who were negative. The kinetics of the endomysial antibody are not yet known and it is possible that these patients may not have had a recent ingestion of gluten. Our results, however, were obtained from a predominantly adult population and indicate that endomysial antibody is found in all untreated patients.
The exact nature of the endomysial antibody is still unknown, recently Karpati et all' have observed IgA antibodies from patients with dermatitis herpetiformis that bind to the normal human jejunum. These jejunal antibodies showed similarities to both IgA antireticulin antibodies and endomysial antibody. They showed that the binding of these antibodies to intestinal tissue was comparable with the IgA deposits seen in small bowel biopsy samples from patients with dermatitis herpetiformis and coeliac disease.32 In a further study Karpati et all showed that 13 of 14 untreated children with coeliac disease had jejunal antibodies and only one of 21 were positive after a gluten free diet although 90% of patients on a gluten challenge showed a reappearance of the jejunal antibodies. This antibody could not be demonstrated in 53 disease control patients with normal jejunal morphology or in three patients with coeliac disease with a selective IgA deficiency. In their studies they simultaneously determined concentrations of antigliadin, endomysial and jejunal antibodies. Using absorption studies with jejunal and antigliadin antibodies they found that jejunal antibodies and antigliadin antibodies were different whereas jejunal antibodies and endomysial antibodies were probably identical. The authors suggested that IgA jejunal antibodies could be the 'target organ related' autoantibody in coeliac disease. A report this year from Karpati et alh further corroborates their suggestion that the endomysial antibody and jejunal antibody are identical.
Halstrom et al, however, ' was unable to distinguish between IgA antigliadin antibodies reacting with human tissues and endomysial antibodies reacting with monkey oesophagus in his absorption studies. We found that the endomysial antibody was very similar but not identical to the antireticulin antibody shown on rat kidney.
Antigliadin antibodies in our study have again shown that they are not specific for the disease. They were found in all disease control groups as well as in normal controls and the specificity was only slightly improved with the IgA antigliadin antibody. The results are disappointing and reiterate results in previous studies.
We conclude that in our hands the endomysial and antireticulin antibodies are very similar, although the endomysial antibody is more sensitive. The endomysial antibody fluorescence is cleaner and easier to read than the antireticulin antibodies and therefore we suggest that this is the optimum screening test for use within a routine laboratory. Tissue sections are available commercially and actual technique is routine in most immunology laboratories.
